Cn. Bernstein et al., Development of an assay for antibodies to Saccharomyces cerevisiae: Easy, cheap and specific for Crohn's disease, CAN J GASTR, 15(8), 2001, pp. 499-504
OBJECTIVE: To develop a serological test to measure antibodies to Saccharom
yces cerevisiae in patients with inflammatory bowel disease.
METHODS: An ELISA to the mannan of S cerevisiae that is commercially availa
ble was developed. Sera were tested from randomly chosen sera specimens kep
t frozen at the University of Manitoba Inflammatory Bowel Disease Clinical
and Research Centre, Winnipeg, Manitoba. Clinical diagnoses were kept blind
ed until the assay results were finalized. One hundred thirty-six sera were
tested, including 51 with Crohn's disease, 32 with ulcerative colitis, one
with indeterminate colitis and 16 other control subjects. Thirty-six sampl
es were duplicates from patients already studied but were either run on sep
arate days or drawn on different days.
RESULTS: Using a cutoff of 15 binding units as a positive result, Crohn's d
isease was found to have a sensitivity of 53% but a specificity of 100% com
pared with ulcerative colitis. Compared with all other diagnoses (including
ulcerative colitis), Crohn's disease had a sensitivity of 53% and a specif
icity of 96%. For patients with Crohn's disease only, those who were anti-S
cerevisiae antibody (ASCA) positive (n=27) were significantly more likely
to have proximal gastrointestinal disease and significantly less likely to
have colonic or inflammatory type disease than those who were ASCA negative
(n=24). The direct cost of this assay was $6.00 per positive test, and the
total charge was set at $38.15.
CONCLUSIONS: A reasonably inexpensive, easy and reproducible assay to asses
s for antibodies to S cerevisiae has been developed. Using a cutoff for pos
itivity of 15 binding units, this test had a specificity of 100% for ruling
out Crohn's disease and a lower (60%) sensitivity compared with ulcerative
colitis. This test could identify a specific phenotype of patients with Cr
ohn's disease as being more likely to have small bowel Crohn's disease and
less likely to have colonic (isolated) or inflammatory disease, as opposed
to fibrostenotic disease or penetrating disease. The test proved reliable w
hen assaying samples drawn or assayed on different days.